Shares of Cempra, Inc. (NASDAQ:CEMP) have been given an average rating of “Hold” by the twenty analysts that are covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $8.70.
A number of research firms recently weighed in on CEMP. Vetr raised shares of Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 target price for the company in a research report on Monday, May 1st. Zacks Investment Research downgraded shares of Cempra from a “buy” rating to a “hold” rating in a research report on Wednesday, May 3rd. ValuEngine downgraded shares of Cempra from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $3.00 price objective on shares of Cempra in a research report on Thursday, May 25th.
COPYRIGHT VIOLATION WARNING: This article was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://stocknewstimes.com/2017/07/28/cempra-inc-cemp-given-consensus-recommendation-of-hold-by-brokerages.html.
Large investors have recently made changes to their positions in the stock. Asset Management One Co. Ltd. bought a new stake in shares of Cempra during the first quarter valued at about $106,000. Janney Montgomery Scott LLC raised its stake in shares of Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 6,800 shares during the period. UBS Asset Management Americas Inc. bought a new stake in shares of Cempra during the first quarter valued at about $140,000. Levin Capital Strategies L.P. raised its stake in shares of Cempra by 56.5% in the first quarter. Levin Capital Strategies L.P. now owns 49,349 shares of the biotechnology company’s stock valued at $185,000 after buying an additional 17,825 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in shares of Cempra during the first quarter valued at about $187,000. 52.48% of the stock is currently owned by institutional investors.
Shares of Cempra (CEMP) opened at 4.20 on Friday. Cempra has a 1-year low of $2.55 and a 1-year high of $26.95. The firm’s market cap is $220.51 million. The company has a 50 day moving average of $4.25 and a 200 day moving average of $3.80.
Cempra (NASDAQ:CEMP) last released its earnings results on Friday, April 28th. The biotechnology company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.16. The business had revenue of $4.87 million during the quarter, compared to the consensus estimate of $3.55 million. Cempra had a negative net margin of 551.45% and a negative return on equity of 56.60%. During the same quarter last year, the firm earned ($0.61) earnings per share. On average, equities analysts forecast that Cempra will post ($1.06) earnings per share for the current fiscal year.
Cempra Company Profile
Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).
Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
